CONy 2015 Webcasts

Is the peer review process obsolete?
Sabina Alam, UK

Undersatnding white matter lesions: Point-to-point correlations between in situ post-mortem MRI and histology
Edson Amaro, Brazil

Empedocles and neurosciences
Stavros Baloyannis, Greece

Meditation and mindfulness as cognitive enhancers
Yoram Barak, Israel

Antibodies and CGRP will change the face of migraine treatment
Marcelo Bigal, USA

Creating wellness as an evolutionary paradigm for medicine
Ewa Stelmasiak, Poland

Does the concept of concomitant neurodegenerative disease have any influence on clinical practice and therapy?
Lea Grinberg, USA/Brazil

Epigenetics in neurodegenerative diseases
Tiago Fleming Outeiro, Germany

Ethical and legal implications of neuro-enhancement
Judit Sándor, Hungary

Welcome remarks and invitation to 2016 in Lisbon
László Vécsei, Hungary

Welcome remarks and invitation to 2016 in Lisbon
Amos D. Korczyn, Israel

Medically unexplained symptoms
Amos D. Korczyn, Israel

Debate: Discontinuation of disease-modifying therapies in patients with long-term stable disease is safe and appropriate
Yes: Cris Constantinescu, UK

Debate: Is the measurement of brain atrophy the most suitable surrogate marker of MS progression?
Host: Mark Freedman, Canada

Debate: ADEM is a condition that can be clinically and pathologically differentiated from MS and NMO
No: Zsolt Illes, Denmark

Generics: Dimitrios Karussis, Israel

Debate: In MS a disease or a syndrome?
Host: Gabor Kovacs, Austria

Debate: In MS a disease or a syndrome?
No: Hans Lassmann, Austria

Ethical drugs: Ron Milo, Israel

Aubagio: Celia Oreja-Guevara, Spain

Debate: Is the measurement of brain atrophy the most suitable surrogate marker of MS progression?
No: Uroš Rot, Slovenia

Debate: Immunomodulators for MS: Generics vs. Ethical drugs
Host: Krzysztof Selmaj, Poland

Debate: Is the measurement of brain atrophy the most suitable surrogate marker of MS progression?
Yes: Olaf Stüve, USA

Debate: ADEM is a condition that can be clinically and pathologically differentiated from MS and NMO
Host: Patrick Vermersch, France

 

Debate: ADEM is a condition that can be clinically and pathologically differentiated from MS and NMO
Yes: Brian Weinshenker, USA

Debate: The new drugs should not be used as first line agents
Host: Heinz Wiendl, Germany

 

Debate: Should antiepileptic drugs (AED's) be started after a first seizure in patients who have pre-existing brain injury?
Host: Christoph Baumgartner, Austria

Debate: Should antiepileptic drugs (AED's) be started after a first seizure in patients who have pre-existing brain injury?
No: Ettore Beghi, Italy

Debate: 50-75% reduction in seizure frequency after is not a meaningful improvement in seizure control
Yes: Elinor Ben Menachem, Sweden

Debate: 50-75% reduction in seizure frequency after is not a meaningful improvement in seizure control
Host: Paul Boon, Belgium

Debate: AED's should not ever be stopped after epilepsy surgery
No: András Fogarasi, Hungary

Debate: It is important and useful to establish a diagnosis of either focal or generalized epilepsy when epilepsy is first diagnosed
Host: Peter Halász, Hungary

Debate: Should epilepsy ever be diagnosed after a single seizure has occurred?
Host: Konrad Rejdak, Poland

Debate: Should epilepsy ever be diagnosed after a single seizure has occurred?
No: Manjari Tripathi, India

Debate: It is important and useful to establish a diagnosis of either focal or generalized epilepsy when epilepsy is first diagnosed
Yes: William Theodore, USA

Debate: 50-75% reduction in seizure frequency after is not a meaningful improvement in seizure control
No: Ilan Blatt, Israel

Debate: PD starts in the gut
Host: Ubaldo Bonuccelli, Italy

Debate: Prevention and modern therapy
Host: Stuart H. Isaacson, USA

Debate: Is levodopa the optimal treatment in PD?
Host: Péter Klivényi, Hungary

Debate: Is levodopa the optimal treatment in PD?
Levodopa is the gold standard but treatment should start with a dopamine agonist: Spiros Konitsiotis, Greece

Debate: Is levodopa the optimal treatment in PD?
Levodopa is the gold standard: Irena Rektorova, Czech Republic

Debate: Is the effect of MAO-B inhibitors clinically relevant? Is safinamide better than selegiline and rasagiline?
No: Maja Relja, Croatia

Lecture: Disease course modification in PD
Amos D. Korczyn, Israel

Debate: Prion-like spreading is a relevant theory for neurodegenerative diseases
Still unproven:
Amos D. Korczyn, Israel

Ultrasound lesioning has a wider role in treatment of movement disorders:
Ilana Schlesinger, Israel

Debate: Are we ready for prevention trials in non-symptomatic individuals?
Not yet, need more information and tools: Panos Alexopoulos, Germany

Debate: Does inflammation contribute to the development of post-stroke dementia?
No: Bernhard Baune, Australia

Debate: Does inflammation contribute to the development of post-stroke dementia?
Host: Herbert Budka, Austria

Debate: Is dementia research ready for big data approaches?
Yes: Keith Elliston, USA

Debate: Does inflammation contribute to the development of post-stroke dementia?
Partner in crime: Dieter Heiss, Germany

Debate: Is dementia research ready for big data approaches?
Host: Martin Hofmann-Apitius, Germany